Pershing Square Capital
View Older Stories View More Recent Stories
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of April 19 2016
-
U.S. activist investors finding fewer opportunities; compromise more common
-
Lone Pine's Cypress Fund down 8 percent in first quarter, hurt by Valeant
-
Does Ackman's Film on Herbalife (HLF) Have A Disclosure Problem?
-
Exclusive: Valeant calls in investment banks to weigh options - sources
-
Legg Mason's Miller Thinks Valeant (VRX) Stock Could Double, Has Been Buying Shares
-
S&P Downgrades Valeant Pharma (VRX) to 'B'; Notes Escalation in Near-Term Default Risk
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of April 12 2016
-
Hedge funds' billion-dollar club loses members in 2015
-
Herbalife (HLF) on Watch Ahead of 'Betting on Zero' Premiere
-
Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb
-
Pershing Square NAV/Share Up Modestly in April; YTD Return Ticked Higher Last Week
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of April 5 2016
-
Valeant Pharma (VRX) Ramps to Session Highs
-
Ackman says Valeant may find new CEO in weeks, not months
-
Pershing Square's Ackman Says Valeant (VRX) was Passive Holding Until Recent, Board Focused on CEO Search
-
Ackman to face investor grilling after record quarterly loss
-
Pershing Square Holdings, Ltd. Releases Monthly Net Asset Value and Performance Report for March 2016
-
Ackman's fund falls 7 percent in March, hurt by Valeant
-
ThanksUSA Opens 2016 Scholarship Application Season for Military Families
-
Pershing Square Holdings, Ltd. (“PSH”) U.S. Shareholders Tax Reporting Information (PFICs)
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Valeant CEO subpoenaed to testify before U.S. Senate panel
-
Senate's request for info from Ackman related to Valeant: source
-
Fitch: Pershing Square Holdings' 'BBB+' Ratings Not Yet Impacted by Valeant Decline
-
Ackman Doesn't See 'Slap on the Wrist' for Herbalife (HLF)
-
Ackman Sees Confidence Restored in Valeant Pharma (VRX) After 10-K Filed, New Leadership Identified
-
Ackman's hedge fund cooperating with U.S. on drug pricing probe: letter
-
Pershing Square Holdings Announces Annual General Meeting in Guernsey and Issues Annual Report and Financial Statements
-
Pershing Square cooperating with U.S. probe - Reuters
-
Valeant Pharma (VRX) Enters Information Sharing Agreement with Pershing Square
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of March 22 2016
-
Ackman Skipping Sohn Investment Conference to Focus on Valeant (VRX)
-
The Howard Hughes Corporation® Issues Letter to Shareholders
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Drugmaker Valeant CEO leaving as investor Ackman joins board
-
Valeant Pharma (VRX) to Replace CEO Pearson; Adds Bill Ackman to Board
-
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update
-
Activist hedge funds wounded by market turmoil
-
S&P says it may cut Ackman hedge fund's rating
-
S&P Places Pershing Square Ratings on CreditWatch Negative; Notes Drop in Performance (VRX)
-
Pershing Square Holdings Ltd. may be cut by S&P
-
Pre-Open Stock Movers 03/17: (VTAE) (RSTI) (AQXP) Higher; (SXE) (ORPN) (SALT) Lower (more...)
-
Form SC 13D/A Mondelez International, Filed by: Pershing Square Capital Management, L.P.
-
After-Hours Stock Movers 03/16: (VTAE) (RSTI) (FDX) Higher; (GES) (SALT) (JBL) Lower (more...)
-
Ackman sells part of Mondelez stake, has no plans for other sales
-
Ackman's Pershing Square Trims Stake in Mondelez Int'l (MDLZ) to 5.6%
-
Pershing Square Holdings, Ltd. Releases Communication to Investors and Regular Weekly Net Asset Value as of 15 March 2016
-
Valeant's stock rout serves up $5.3 billion in hedge fund losses

